Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-103: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-103: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs ODM 103 (Primary) ; Entacapone; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Pharmacodynamics
  • Acronyms NOCOS
  • Sponsors Orion Pharma
  • Most Recent Events

    • 18 Sep 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
    • 01 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 08 Aug 2013 Planned end date changed from 1 Sep 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top